Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.37
-0.70 (-2.25%)
At close: Jan 30, 2026, 4:00 PM EST
30.34
-0.03 (-0.10%)
After-hours: Jan 30, 2026, 4:20 PM EST
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $10.63M in the quarter ending September 30, 2025, with 117.25% growth. This brings the company's revenue in the last twelve months to $205.63M, up 1,128.17% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$205.63M
Revenue Growth
+1,128.17%
P/S Ratio
8.55
Revenue / Employee
$1,606,500
Employees
128
Market Cap
1.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 313.79M |
| Zymeworks | 134.48M |
| Syndax Pharmaceuticals | 111.30M |
| Nurix Therapeutics | 83.98M |
| Nuvation Bio | 26.75M |
| Upstream Bio | 2.80M |
STOK News
- 4 days ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 15 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 16 days ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 20 days ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 25 days ago - Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire